Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sac-TMT plus pembrolizumab versus pembrolizumab alone as first-line maintenance therapy for pMMR endometrial cancer
CTR20252559Phase 3Active
- Sponsor
- MSD
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan, pembrolizumab in endometrial cancer (EC), sponsored by MSD. Started Jan 2026; status: active.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20252559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252559.